CYP2C9 genotype vs. metabolic phenotype for individual drug dosing-A correlation analysis using flurbiprofen as probe drug

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Vogl, Silvia ^a,b   Lutz, Roman W ^c   Schönfelder, Gilbert ^a,b,d   Lutz, Werner K ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c ETH ZURICH   (Switzerland)

^d FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; FLURBIPROFEN; PRODRUG; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYP2C9 1 GENE; CYP2C9 2 GENE; CYP2C9 3 GENE; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; INDIVIDUAL DRUG DOSING; LIQUID CHROMATOGRAPHY; MALE; METABOLIC PHENOTYPE; NORMAL HUMAN; PHENOTYPE; PREDICTIVE VALUE; STATISTICAL MODEL; TANDEM MASS SPECTROMETRY; URINARY METABOLIC RATIO; WILD TYPE; YOUNG ADULT; ALLELE; CHEMISTRY; GENETIC ASSOCIATION STUDY; GENETICS; METABOLISM; PHARMACOGENETICS;

ADULT; ALLELES; CYCLOOXYGENASE INHIBITORS; CYTOCHROME P-450 CYP2C9; FEMALE; FLURBIPROFEN; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; PHARMACOGENETICS; PHENOTYPE; PRODRUGS; YOUNG ADULT;

EID: 84925004475     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120403     Document Type: Article

References (36)

1. Zhou SF, Zhou ZW, Huang M. Polymorphisms of Human Cytochrome P450 2C9 and the Functional Relevance. Toxicology. 2009;278:165-188. doi: 10.1016/j.tox.2009.08.013 PMID: 19715737
2. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41:89-295. doi: 10.1080/03602530902843483 PMID: 19514967
3. Stehle S, Kirchheiner J, Lazar A, Fuhr U. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet. 2008;47:565-594. PMID: 18698879
4. Kirchheiner J, Tsahuridu M, Jabrane W, Roots I, Brockmöller J. The CYP2C9 polymorphism: from enzyme to clinical dose recommendations. Personalized Med. 2004;1:63-84.
5. Wadelius M, Sorlin K, Wallerman O, Karlsson J, Yue QY, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J. 2004;4:40-48. PMID: 14676821
6. Conrado DJ, Rogers HL, Zineh I, Pacanowski MA. Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels. Pharmacogenomics. 2013;14:215-223. doi: 10.2217/pgs.12.203 PMID: 23327581
7. Magdalou J, Chajes V, Lafaurie C, Siest G. Glucuronidation of 2-arylpropionic acids pirprofen, flurbiprofen, and ibuprofen by liver microsomes. Drug Metab Dispos. 1990;18:692-697. PMID: 1981722
8. Zgheib NK, Frye RF, Tracy TS, Romkes M, Branch RA. Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity. Br J Clin Pharmacol. 2007;63:477-487. PMID: 17054666
9. Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, et al. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol. 2003;43:84-91. PMID: 12520632
10. ∗3 genotypes. Eur J Clin Pharmacol. 2003;58:791-794. PMID: 12698304
11. Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Harmatz JS, et al. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther. 2006;79:125-133. PMID: 16413247
12. Greenblatt DJ, von Moltke LL, Luo Y, Perloff ES, Horan KA, et al. Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J Clin Pharmacol. 2006;46:214-221. PMID: 16432273
13. Daali Y, Samer C, Deglon J, Thomas A, Chabert J, et al. Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot. Clin Pharmacol Ther. 2012;91:489-496. doi: 10.1038/clpt.2011. 247 PMID: 22237256
14. Verhoef TI, Redekop WK, Daly AK, van Schie RM, de Boer A, et al. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. Br J Clin Pharmacol. 2014;77:626-641. doi: 10.1111/bcp. 12220 PMID: 23919835
15. Wu AH, Wang P, Smith A, Haller C, Drake K, et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics. 2008;9:169-178. doi: 10.2217/14622416.9.2.169 PMID: 18370846
16. Castellan AC, Tod M, Gueyffier F, Audars M, Cambriels F, et al. Quantitative Prediction of the Impact of Drug Interactions and Genetic Polymorphisms on Cytochrome P450 2C9 Substrate Exposure. Clin Pharmacokinet. 2013;52:199-209. doi: 10.1007/s40262-013-0031-3 PMID: 23344982
17. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005;77:1-16. PMID: 15637526
18. Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics. 2002;12:101-109. PMID: 11875364
19. Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, et al. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics. 2009;19:170-179. doi: 10.1097/FPC.0b013e32831ebb30 PMID: 19151603
20. Tracy TS, Rosenbluth BW, Wrighton SA, Gonzalez FJ, Korzekwa KR. Role of cytochrome P450 2C9 and an allelic variant in the 40-hydroxylation of (R) - and (S)-flurbiprofen. Biochem Pharmacol. 1995;49:1269-1275. PMID: 7763308
21. Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR. Studies of flurbiprofen 40-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem Pharmacol. 1996;52:1305-1309. PMID: 8937439
22. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353:717-719. PMID: 10073515
23. Topic E, Stefanovic M, Samardzija M. Association between the CYP2C9 polymorphism and the drug metabolism phenotype. Clin Chem Lab Med. 2004;42:72-78. PMID: 15061384
24. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarintreated patients: a HuGEnet systematic review and meta-analysis. Genet Med. 2005;7:97-104. PMID: 15714076
25. Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J. 2005;5:193-202. PMID: 15824753
26. Zhou SF, Di YM, Chan E, Du YM, Chow VD, et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab. 2008;9:738-784. PMID: 18855611
27. Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, et al. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol. 1998;56:243-251. PMID: 9698079
28. ∗5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab Dispos. 2002;30:385-390. PMID: 11901091
29. Zgheib NK, Frye RF, Tracy TS, Romkes M, Branch RA. Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Clin Pharmacol Ther. 2006;80:257-263. PMID: 16952492
30. Zhang SY, Surapureddi S, Coulter S, Ferguson SS, Goldstein JA. Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver. Mol Pharmacol. 2012;82:529-540. doi: 10.1124/mol.112.078386 PMID: 22723340
31. Subramanian M, Low M, Locuson CW, Tracy TS. CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis. Drug Metab Dispos. 2009;37:1682-1689. doi: 10.1124/dmd.109.026500 PMID: 19448135
32. Ramsden D, Tweedie DJ, Chan TS, Tracy TS. Altered CYP2C9 activity following modulation of CYP3A4 levels in human hepatocytes: an example of protein-protein interactions. Drug Metab Dispos. 2014;42:1940-1946. doi: 10.1124/dmd.114.057901 PMID: 25157098
33. Subramanian M, Tam H, Zheng H, Tracy TS. CYP2C9-CYP3A4 protein-protein interactions: role of the hydrophobic N terminus. Drug Metab Dispos. 2010;38:1003-1009. doi: 10.1124/dmd.109.030155 PMID: 20215413
34. Temesvari M, Kobori L, Paulik J, Sarvary E, Belic A, et al. Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression. J Pharmacol Exp Ther. 2012;341:294-305. doi: 10. 1124/jpet.111.189597 PMID: 22262920
35. Bosilkovska M, Clement M, Dayer P, Desmeules J, Daali Y. Incorporation of Flurbiprofen in a 4-Drug Cytochrome P450 Phenotyping Cocktail. Basic & Clinical Pharmacology & Toxicology. 2014;115:465-466.
36. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996;6:341-349. PMID: 8873220